Annual Report

Overview

The report is TYK Medicines' first ESG report, covering January 1-December 31, 2024 and prepared under HKEX's ESG Reporting Code. It highlights the company's 2024 R&D progress, including 110 R&D personnel and total R&D investment of RMB235 million. Environmental disclosures report Scope 1 emissions of 52.89 tCO2e and Scope 2 emissions of 933.21 tCO2e, alongside a 2026 GHG-intensity reduction target of approximately 3% to 5%. The company reports 153 employees and no work-related fatalities.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 27 March 2025
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services